Heart Failure News and Research RSS Feed - Heart Failure News and Research

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.
Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). [More]
Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra. [More]
Rapid cooling procedures prior to catheterization reduce extent of myocardial infarction

Rapid cooling procedures prior to catheterization reduce extent of myocardial infarction

After an acute myocardial infarction, patients treated with rapid lowering of body temperature by combined cold saline infusion and endovascular cooling had less heart muscle damage and reduced incidence of heart failure. Therapeutic hypothermia was especially protective against heart muscle damage in patients with a large area of myocardium at risk according to an analysis of two clinical trials published in Therapeutic Hypothermia and Temperature Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Images revealing structure of heart cell may provide clues to reducing heart attack damage

Images revealing structure of heart cell may provide clues to reducing heart attack damage

Newly released images revealing the 'bicycle spoke' structure of a heart cell may hold key clues to reducing damage from a heart attack. [More]
Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States. [More]
Glucose-control drug sitagliptin does not raise risk of cardiovascular events

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events. [More]
Scientists develop computational method to study link between birth month and disease risk

Scientists develop computational method to study link between birth month and disease risk

Columbia University scientists have developed a computational method to investigate the relationship between birth month and disease risk. [More]
Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk. [More]
Physicians at UH Case Medical Center implant revolutionary device to treat right ventricular heart disease

Physicians at UH Case Medical Center implant revolutionary device to treat right ventricular heart disease

University Hospitals Case Medical Center physicians in the Harrington Heart & Vascular Institute were the first in the state of Ohio to implant a revolutionary device to treat right ventricular heart disease. [More]
Withholding ARBs for longer than two days after surgery significantly increases risk of postoperative death

Withholding ARBs for longer than two days after surgery significantly increases risk of postoperative death

Withholding angiotensin receptor blockers (ARBs) for longer than two days after surgery is associated with a significantly increased risk of postoperative death, according to a study of more than 30,000 patients in the VA health care system by researchers at UC San Francisco and the San Francisco VA Medical Center. [More]
Cytokinetics, The ALS Association expand partnership to fight against ALS

Cytokinetics, The ALS Association expand partnership to fight against ALS

Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives. [More]
Cyberonics announces results for fourth quarter and fiscal year 2015

Cyberonics announces results for fourth quarter and fiscal year 2015

Cyberonics, Inc. today announced results for the fourth quarter and fiscal year ended April 24, 2015. [More]
Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Day in and day out, for years on end, millions of people with diabetes prick their fingers to test their blood sugar level. And many may wonder if all the careful eating, exercise and medication it takes to keep those levels under control is really worth it. [More]
Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional care has emerged as a way to reduce hospital readmissions, and progressive care nurses can play an integral role in efforts to help patients achieve functional recovery faster in post-acute care, according to an article in the June issue of Critical Care Nurse. [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
Using earlier surgical intervention more beneficial to patient with degenerative mitral valve disease

Using earlier surgical intervention more beneficial to patient with degenerative mitral valve disease

A more aggressive approach to treating degenerative mitral valve disease, using earlier surgical intervention and less invasive techniques, is more beneficial to the patient than "watchful waiting," according to an article in the June 2015 issue of The Annals of Thoracic Surgery. [More]
Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

The Lancet Diabetes & Endocrinology is pleased to announce that the following paper will be published to coincide with presentation at the 52nd ERA-EDTA Congress, taking place in London, UK, May 28 - 31, 2015. [More]
Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma. [More]
Advertisement